Quick Answer
NewAmsterdam Pharma Co N.V. reported R&D Expense of $141.83 million for fiscal year 2025.
NewAmsterdam Pharma Co N.V. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $141.83M | -6.3% |
| 2024 | $151.41M | -5.0% |
| 2023 | $159.42M | +83.8% |
| 2022 | $86.74M | +199.4% |
| 2021 | $28.97M | +616.3% |
| 2020 | $4.04M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $30.97M | -13.3% | +12.6% |
| June 30, 2025 | $27.52M | -28.3% | -38.5% |
| March 31, 2025 | $44.75M | +5.5% | +25.3% |
| September 30, 2024 | $35.70M | -17.7% | -7.0% |
| June 30, 2024 | $38.38M | +11.8% | -9.5% |
| March 31, 2024 | $42.43M | +5.0% | -2.2% |
| September 30, 2023 | $43.37M | — | +26.3% |
| June 30, 2023 | $34.34M | — | -15.0% |
- NewAmsterdam Pharma Co N.V. showed a decrease of -6.3% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, NewAmsterdam Pharma Co N.V.’s r&d expense has grown by 3406.4% (from $4.04 million to $141.83 million).
- The most recent figure is from NewAmsterdam Pharma Co N.V.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 18, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: